查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961247

魚類疫苗市場－全球產業規模、佔有率、趨勢、機會和預測：按疫苗類型、給藥途徑、地區和競爭情況分類，2021-2031年

Fish Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球魚類疫苗市場預計將從 2025 年的 4.3338 億美元成長到 2031 年的 5.8711 億美元，複合年成長率為 5.19%。

這些生物製藥對於刺激養殖魚類的免疫系統、賦予其對特定病原體的主動適應性免疫至關重要。此領域的發展主要受全球水產養殖業集約化發展的推動。養殖密度的增加提高了疾病傳播的風險，因此需要嚴格的預防性健康管理通訊協定。此外，該行業正優先考慮疫苗接種策略，以減少對抗生素的依賴，實施抗菌素抗藥性措施，並遵守嚴格的食品安全法規。全球海鮮聯盟的數據也反映了這種在這些法規下對永續性的承諾，該聯盟報告稱，到2024年，獲得認證的負責任水產養殖設施數量將增加5%，達到全球整體4168家。

市場概覽
預測期 2027-2031
市場規模：2025年 4.3338億美元
市場規模：2031年 5.8711億美元
複合年成長率：2026-2031年 5.19%
成長最快的細分市場 去活化疫苗
最大的市場 北美洲

然而，市場成長面臨許多重大障礙，例如複雜的物流以及在各種水生環境中為大規模人群接種疫苗的高昂成本。為低價值物種建立經濟可行且高效的供應體系仍然是生產者面臨的持續挑戰。這些財務和營運障礙在發展中地區尤其嚴峻，因為小規模農戶往往缺乏實施先進疾病控制策略所需的資源。因此，儘管水生病原體的傳播持續加劇，但這種差距可能會限制市場滲透，並使確保這些基本衛生措施廣泛應用的努力變得更加複雜。

市場促進因素

全球水產養殖業的快速擴張對疾病預防措施的需求激增，並從根本上改變了魚類疫苗市場。隨著產量擴大以滿足全球糧食安全需求，商業水產養殖中採用的高密度養殖方式顯著增加了養殖魚類對病原體爆發的易感性，因此實施系統性免疫通訊協定至關重要。此次產量激增標誌著歷史性的轉折點，養殖產量首次超過野生漁獲量。根據聯合國糧食及農業組織（糧農組織）2024年6月發布的《2024年全球漁業及水產養殖狀況》報告，2022年全球養殖產量達到創紀錄的1.309億噸，首次超過野生漁獲量。如此大規模的養殖活動增加了生物風險，凸顯了強力的預防性健康管理解決方案的經濟必要性，挪威獸醫研究所 2024 年 3 月的報告就證明了這一點，該報告記錄了 2023 年 6270 萬條養殖鮭魚的死亡情況。

同時，新型疫苗研發和供應的技術進步正在推動市場發展，使人們能夠精準應對以往難以解決的病毒和細菌威脅。該行業正從簡單的去活化疫苗發展到利用先進的基因組分析和重組技術，為各種水生環境提供廣泛保護和高效給藥的解決方案。這一創新趨勢的推動力來自政府為實現水生動物健康管理現代化和減少抗生素依賴而提供的資金。例如，2024年2月，美國農業部（USDA）宣布透過「水產養殖研究津貼計畫」提供約193.6萬美元的資金，用於支持針對關鍵產業挑戰（包括疾病管理）的應用研究。這些資金和技術資源正在加速下一代疫苗的商業化，使生產者能夠在遵守永續生產標準的同時最大限度地減少損失。

市場挑戰

大規模魚群疫苗接種涉及複雜的物流和高昂的營運成本，這給全球魚類疫苗市場帶來了巨大的障礙。雖然注射仍然是確保疫苗高效性的標準方法，但對於佔全球水產養殖業大多數的低價值魚類和小規模養殖戶而言，注射既費時費力又昂貴。這種經濟差距迫使發展中地區的生產者採用永續性較差的管理方法，阻礙了市場向大規模生產領域的擴張。因此，研發適用於不同水生環境的給藥機制所需的研發成本難以得到充分論證，形成了一個惡性循環，阻礙了那些亟需資金支持的預防性健康措施的實施。

這些營運限制直接反映在生物量的持續成長上，顯示市場尚未克服有效且廣泛供應的挑戰。據挪威海鮮協會（Seafood Norway）稱，2024年養殖鮭魚的海洋死亡率達到15.4%。這項數據凸顯了疫苗供應與實際應用之間持續存在的差距，表明物流和成本方面的障礙正在有效地限制市場潛力，阻礙了全面疾病控制，而全面疾病控制對於保護該行業免受長期存在的健康威脅至關重要。

市場趨勢

擴大針對特定水產養殖場的自研疫苗生產，滿足了快速應對標準核准產品無法覆蓋的病原體的迫切需求。這些客製化疫苗採用直接從特定養殖場分離的病原體研製而成，能夠精準標靶化特定區域的病原體，彌補了大眾市場產品監管核准速度跟不上病毒變異速度的巨大缺口。這種客製化策略對於控制無法用通用配方控制的局部疫情尤其重要。 AquaTactics公司獲得美國農業部（USDA）核准生產自研魚類疫苗，正是該子部門發展的一個例證。正如FishSight在2025年3月發表的報導《USDA濕實驗室核准助力AquaTactics進軍自研疫苗市場》中所報道，這使得該公司能夠為全美各地的水產養殖設施提供客製化的健康解決方案。

同時，針對溫水和新興物種的疫苗研發正將產業的重心從現有的鮭科魚類轉向蝦類等高產量養殖領域。製造商正在開發新的預防技術，以應對無脊椎動物獨特的免疫挑戰，而先前針對這些無脊椎動物的有效疾病控制一直匱乏。這種多元化對於減輕溫水環境中病毒爆發造成的嚴重損失至關重要，而傳統上，溫水環境的疫情控制主要依賴抗生素和人為控制。大蘭動物保健公司正是這項創新發展軌跡的典型代表。根據《國家食品供應商》2025年11月發表的一篇報導《大蘭動物保健公司將推出蝦類疫苗以應對水產養殖業挑戰》的文章報道，該公司已成功資金籌措300萬美元，用於將全球首款蝦類疫苗商業化，直接滿足全球水產養殖業的關鍵需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球魚類疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疫苗類型（去活化疫苗、減毒疫苗、類毒素疫苗、次單位疫苗疫苗、結合疫苗、重組載體疫苗）
    • 給藥途徑（注射、浸泡、噴霧、口服）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美魚類疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲魚類疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區魚類疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲魚類疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲魚類疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球魚類疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck Sharp & Dohme LLC
  • Zoetis Services LLC
  • Elanco Animal Health Incorporated
  • Virbac SA
  • HIPRA, SA
  • Veterquimica SA
  • Phibro Animal Health Corporation
  • Ridgeway Biologicals Ltd
  • Nisseiken Co., Ltd.
  • Benchmark Holdings PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24520

The Global Fish Vaccine Market is projected to expand from USD 433.38 Million in 2025 to USD 587.11 Million by 2031, reflecting a compound annual growth rate (CAGR) of 5.19%. These biological preparations are critical for stimulating the immune systems of aquaculture species, conferring active acquired immunity against specific pathogens. Growth in this sector is largely propelled by the intensification of global aquaculture, where elevated stocking densities heighten the risk of disease transmission, thereby requiring rigorous preventative health protocols. Additionally, the industry is increasingly prioritizing vaccination strategies to decrease dependence on antibiotics, combat antimicrobial resistance, and adhere to stringent food safety regulations. This dedication to regulated sustainability is highlighted by data from the Global Seafood Alliance, which noted a 5% rise in certified responsible aquaculture facilities in 2024, reaching a total of 4,168 locations worldwide.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 433.38 Million
Market Size 2031USD 587.11 Million
CAGR 2026-20315.19%
Fastest Growing SegmentInactivated Vaccine
Largest MarketNorth America

However, market growth faces a substantial obstacle in the form of the logistical intricacies and high expenses linked to administering vaccines to large populations across varied aquatic settings. Creating effective delivery systems that are economically feasible for lower-value species poses a persistent difficulty for manufacturers. This financial and operational hurdle is especially severe in developing regions, where small-scale farmers often lack the necessary resources to adopt advanced disease management strategies. Consequently, this disparity threatens to limit market penetration even as the prevalence of aquatic pathogens continues to rise, complicating efforts to secure widespread adoption of these essential health measures.

Market Driver

The rapid expansion of the global aquaculture industry is fundamentally transforming the fish vaccine market by generating massive demand for disease prevention measures. As production scales up to address global food security requirements, the high stocking densities utilized in commercial farming drastically increase stock susceptibility to pathogenic outbreaks, making systemic immunization protocols essential. This production surge is marked by a historic shift where farmed output has exceeded wild capture fisheries. According to the Food and Agriculture Organization (FAO) report 'The State of World Fisheries and Aquaculture 2024' released in June 2024, global aquaculture production hit a record 130.9 million tonnes in 2022, surpassing capture fisheries for the first time. Such immense scaling intensifies biological risks, a reality emphasized by the Norwegian Veterinary Institute's March 2024 report, which documented the death of 62.7 million farmed salmon in 2023, highlighting the economic imperative for robust prophylactic health solutions.

Concurrently, technological advancements in the development and delivery of novel vaccines are driving market momentum by enabling precise targeting of previously difficult viral and bacterial threats. The industry is evolving from simple inactivated bacterins to sophisticated genomic and recombinant solutions that provide wider protection and more efficient administration across diverse aquatic environments. This trend toward innovation is bolstered by government funding designed to modernize aquatic animal health management and curb antibiotic reliance. For example, the U.S. Department of Agriculture (USDA) announced in February 2024, under its 'Special Research Grants for Aquaculture Research' program, that approximately $1.936 million was available to support applied research into critical industry constraints, including disease management. These financial and technical resources are accelerating the commercialization of next-generation vaccines, allowing producers to minimize losses while adhering to sustainable production standards.

Market Challenge

The logistical intricacies and substantial operational costs involved in vaccinating mass populations present a formidable obstacle to the Global Fish Vaccine Market. Although injection remains the gold standard for high efficacy, it creates a labor-intensive and financially burdensome barrier for lower-value species and small-scale operations, which constitute a large share of the global aquaculture landscape. This economic disparity compels producers in developing regions to forego vaccination in favor of less sustainable management methods, effectively impeding market expansion into high-volume segments. As a result, manufacturers struggle to justify the research and development expenditures required to create delivery mechanisms suitable for varied aquatic environments, resulting in a cycle where financial constraints hinder the adoption of essential preventative health measures.

The direct consequence of these operational constraints is reflected in persistent stock losses, indicating that the market has not yet overcome the challenge of effective, widespread delivery. According to the industry organization Seafood Norway, the mortality rate for farmed salmon during the sea phase reached 15.4% in 2024. This statistic highlights the continuing discrepancy between vaccine availability and successful field application, demonstrating how logistical and cost-related barriers effectively limit market potential by preventing the comprehensive disease control necessary to secure the sector against prevalent health threats.

Market Trends

The growth of site-specific autogenous vaccine production is addressing the critical need for rapid-response solutions to pathogens not covered by standard licensed products. These custom vaccines, developed from pathogens isolated directly from specific farms, enable precise immunological targeting of local disease strains, filling a vital gap where regulatory approval for mass-market products cannot keep pace with viral mutations. This bespoke strategy is particularly essential for managing regional outbreaks that generic formulations fail to control. The expansion of this sub-sector is illustrated by AquaTactics receiving USDA approval to manufacture autogenous fish vaccines, as reported by The Fish Site in March 2025 in the article 'USDA Wet Lab Approval Sees AquaTactics Move Into Autogenous Vaccines', which allows for the provision of tailored health solutions to aquaculture facilities throughout the United States.

Simultaneously, targeted vaccine R&D for warm-water and emerging species is redirecting the industry's focus from established salmonid sectors toward high-volume segments such as shrimp. Manufacturers are engineering novel prophylactic technologies to address the distinct immunological challenges of invertebrates, which have historically lacked effective disease control measures. This diversification is crucial for mitigating severe losses caused by viral outbreaks in warm-water environments that previously depended on antibiotics or management adjustments. This trajectory of innovation is exemplified by Dalan Animal Health, which, according to The National Provisioner article 'Dalan Animal Health moves to commercialize shrimp vaccine, targeting aquaculture industry challenges' from November 2025, secured $3 million in funding to commercialize the world's first shrimp vaccine, directly tackling a significant unmet need in global aquaculture.

Key Market Players

  • Merck Sharp & Dohme LLC
  • Zoetis Services LLC
  • Elanco Animal Health Incorporated
  • Virbac S.A.
  • HIPRA, S.A.
  • Veterquimica S.A.
  • Phibro Animal Health Corporation
  • Ridgeway Biologicals Ltd
  • Nisseiken Co., Ltd.
  • Benchmark Holdings PLC

Report Scope

In this report, the Global Fish Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fish Vaccine Market, By Vaccine Type

  • Killed Vaccine
  • Inactivated Vaccine
  • Attenuated Vaccine
  • Toxoid Vaccine
  • Subunit Vaccine
  • Conjugate Vaccine
  • Recombinant Vector Vaccines

Fish Vaccine Market, By Route of Administration

  • Injection
  • Immersion
  • Spray
  • Oral

Fish Vaccine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fish Vaccine Market.

Available Customizations:

Global Fish Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fish Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vaccine Type (Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine, Recombinant Vector Vaccines)
    • 5.2.2. By Route of Administration (Injection, Immersion, Spray, Oral)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Fish Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vaccine Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Fish Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vaccine Type
        • 6.3.1.2.2. By Route of Administration
    • 6.3.2. Canada Fish Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vaccine Type
        • 6.3.2.2.2. By Route of Administration
    • 6.3.3. Mexico Fish Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vaccine Type
        • 6.3.3.2.2. By Route of Administration

7. Europe Fish Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vaccine Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Fish Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vaccine Type
        • 7.3.1.2.2. By Route of Administration
    • 7.3.2. France Fish Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vaccine Type
        • 7.3.2.2.2. By Route of Administration
    • 7.3.3. United Kingdom Fish Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vaccine Type
        • 7.3.3.2.2. By Route of Administration
    • 7.3.4. Italy Fish Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vaccine Type
        • 7.3.4.2.2. By Route of Administration
    • 7.3.5. Spain Fish Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vaccine Type
        • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Fish Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vaccine Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Fish Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vaccine Type
        • 8.3.1.2.2. By Route of Administration
    • 8.3.2. India Fish Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vaccine Type
        • 8.3.2.2.2. By Route of Administration
    • 8.3.3. Japan Fish Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vaccine Type
        • 8.3.3.2.2. By Route of Administration
    • 8.3.4. South Korea Fish Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vaccine Type
        • 8.3.4.2.2. By Route of Administration
    • 8.3.5. Australia Fish Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vaccine Type
        • 8.3.5.2.2. By Route of Administration

9. Middle East & Africa Fish Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vaccine Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Fish Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vaccine Type
        • 9.3.1.2.2. By Route of Administration
    • 9.3.2. UAE Fish Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vaccine Type
        • 9.3.2.2.2. By Route of Administration
    • 9.3.3. South Africa Fish Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vaccine Type
        • 9.3.3.2.2. By Route of Administration

10. South America Fish Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vaccine Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Fish Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vaccine Type
        • 10.3.1.2.2. By Route of Administration
    • 10.3.2. Colombia Fish Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vaccine Type
        • 10.3.2.2.2. By Route of Administration
    • 10.3.3. Argentina Fish Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vaccine Type
        • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Fish Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck Sharp & Dohme LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Zoetis Services LLC
  • 15.3. Elanco Animal Health Incorporated
  • 15.4. Virbac S.A.
  • 15.5. HIPRA, S.A.
  • 15.6. Veterquimica S.A.
  • 15.7. Phibro Animal Health Corporation
  • 15.8. Ridgeway Biologicals Ltd
  • 15.9. Nisseiken Co., Ltd.
  • 15.10. Benchmark Holdings PLC

16. Strategic Recommendations

17. About Us & Disclaimer